Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does 5-FLUOROURACIL Cause Malignant neoplasm progression? 15 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Malignant neoplasm progression have been filed in association with 5-FLUOROURACIL. This represents 2.7% of all adverse event reports for 5-FLUOROURACIL.

15
Reports of Malignant neoplasm progression with 5-FLUOROURACIL
2.7%
of all 5-FLUOROURACIL reports
7
Deaths
4
Hospitalizations

How Dangerous Is Malignant neoplasm progression From 5-FLUOROURACIL?

Of the 15 reports, 7 (46.7%) resulted in death, 4 (26.7%) required hospitalization, and 1 (6.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for 5-FLUOROURACIL. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does 5-FLUOROURACIL Cause?

Breast cancer (137) Neoplasm progression (63) Death (37) Nausea (35) Neutropenia (33) Vomiting (32) Diarrhoea (29) Musculoskeletal disorder (25) Pyrexia (24) Toxicity to various agents (20)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which 5-FLUOROURACIL Alternatives Have Lower Malignant neoplasm progression Risk?

5-FLUOROURACIL vs 5-FU 5-FLUOROURACIL vs 6-ACETYLMORPHINE 5-FLUOROURACIL vs ABACAVIR 5-FLUOROURACIL vs ABACAVIR\DOLUTEGRAVIR\LAMIVUDINE 5-FLUOROURACIL vs ABACAVIR\LAMIVUDINE

Related Pages

5-FLUOROURACIL Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression 5-FLUOROURACIL Demographics